| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 6/6 |
Rewards
Risk Analysis
No risks detected for 300009 from our risk checks.
Anhui Anke Biotechnology (Group) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥9.55 |
| 52 Week High | CN¥11.55 |
| 52 Week Low | CN¥7.56 |
| Beta | 0.52 |
| 1 Month Change | -0.73% |
| 3 Month Change | 5.29% |
| 1 Year Change | -14.04% |
| 3 Year Change | -42.24% |
| 5 Year Change | -2.44% |
| Change since IPO | 207.25% |
Recent News & Updates
Shareholder Returns
| 300009 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.3% | 0.3% | 1.6% |
| 1Y | -14.0% | -24.2% | -15.1% |
Return vs Industry: 300009 exceeded the CN Biotechs industry which returned -24.2% over the past year.
Return vs Market: 300009 exceeded the CN Market which returned -15.1% over the past year.
Price Volatility
| 300009 volatility | |
|---|---|
| 300009 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 300009 has not had significant price volatility in the past 3 months.
Volatility Over Time: 300009's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 2,986 | Lihua Song | www.ankebio.com |
Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name.
Anhui Anke Biotechnology (Group) Co., Ltd. Fundamentals Summary
| 300009 fundamental statistics | |
|---|---|
| Market cap | CN¥15.97b |
| Earnings (TTM) | CN¥847.23m |
| Revenue (TTM) | CN¥2.87b |
18.9x
P/E Ratio5.6x
P/S RatioIs 300009 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300009 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.87b |
| Cost of Revenue | CN¥631.04m |
| Gross Profit | CN¥2.23b |
| Other Expenses | CN¥1.39b |
| Earnings | CN¥847.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 0.51 |
| Gross Margin | 77.98% |
| Net Profit Margin | 29.56% |
| Debt/Equity Ratio | 0% |
How did 300009 perform over the long term?
See historical performance and comparison